EUVIMEDEUVIMED entdecken
Crossref

Clinical Studies of Silymarin as a Protective Agent Against Liver Damage Caused by Anti-TB Drugs, Methotrexate, and in Cases of Chronic Hepatitis C and Diabetes Mellitus

Jimenez-Arellanes Maria Adelina

Pharmacognosy Journal · 04.05.2022 · 14 (2) · 358-368

DOI: 10.5530/pj.2022.14.46 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacognosy Journal, online erschienen am 04.05.2022. Verfasst von Jimenez-Arellanes Maria Adelina. Die Arbeit wurde bisher 3-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Adelina, J. M. (2022). Clinical Studies of Silymarin as a Protective Agent Against Liver Damage Caused by Anti-TB Drugs, Methotrexate, and in Cases of Chronic Hepatitis C and Diabetes Mellitus. Pharmacognosy Journal, 14(2), 358-368. https://doi.org/10.5530/pj.2022.14.46

Vancouver

Adelina JM. Clinical Studies of Silymarin as a Protective Agent Against Liver Damage Caused by Anti-TB Drugs, Methotrexate, and in Cases of Chronic Hepatitis C and Diabetes Mellitus. Pharmacognosy Journal. 2022;14(2):358-368. doi:10.5530/pj.2022.14.46

BibTeX
@article{Adelina2022,
  author = {Adelina, Jimenez-Arellanes Maria},
  title = {Clinical Studies of Silymarin as a Protective Agent Against Liver Damage Caused by Anti-TB Drugs, Methotrexate, and in Cases of Chronic Hepatitis C and Diabetes Mellitus},
  journal = {Pharmacognosy Journal},
  year = {2022},
  volume = {14},
  number = {2},
  pages = {358--368},
  doi = {10.5530/pj.2022.14.46}
}
Kostenlos starten →